mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Maxwell Biotech Group
infectex-slide-001

The first drug in the company's portfolio is SQ109 for the treatment of multidrug-resistant TB (MDR-TB).
The drug is in advanced stage of clinical development.

Load more

infectex-slide-002

The second drug Q203 is the first in new class
of amide imidazopyridine compounds. The drug is
a highly selective inhibitor of M. tuberculosis growth.

Load more

INFECTEX

Infectex is a Russian biotechnology company founded with the goal to develop and bring to the Russian market innovative drugs for the treatment of serious infectious diseases.

To date the Company develops 2 antituberculosis drugs: SQ109 and Q203.

SQ109

mbg-infectex-004

Q203

mbg-infectex-008

Latest news

Top